Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghozlan, P. R.
Right arrow Articles by Bluhmki, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ghozlan, P. R.
Right arrow Articles by Bluhmki, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

Tolerability of Multiple Administration of Intramuscular Meloxicam: A Comparison with Intramuscular Piroxicam in Patients with Rheumatoid Arthritis or Osteoarthritis

P. R. Ghozlan*, M. Bernhardt{dagger}, P. Vélicitat{ddagger} and E. Bluhmki§

* Polyclinique d' Aubervilliers 55 Henri Barbusse, 93308 Aubervilliers Cédex, France
{dagger} Kurklinikam Park, Berliner Strasse 9, 59505 Bad Sassendorf Germany
{ddagger} Boehringcr Ingelheim France, 12rue André Huet, BP292, 51060 Reims Cédex France
§ Boehringer Ingelheim GmbH, Birkendorfer Strasse65, 88397 Biberach/Riss Germany

Correspondence to: Correspondence to: P. Vélicitat, Boehringer Ingelbenn France, 12 rue André Huet, BP 292, 51060 Reims Cédex, France.


  Abstract

This multicentre, randomized, open controlled study compared the local and overall tolerability of i.m. meloxicam with i.m. piroxicam in 211 patients with rheumatoid arthritis (RA) (n = 95) or osteoarthritis (OA) (n = 116). Of these, 210 patients were randomized (2: 1) to receive meloxicam 15 mg (n = 144) or piroxicam 20 mg (n = 66) for 7 days. Local tolerability of meloxicam was significantly better than piroxicam with respect to occurrence of redness after the first injection (P = 0.03) and global assessment after the first and final injections (P < 0.05). No rise in creatinine phosphokinase levels (a marker of muscle fibre damage) was observed with meloxicam, in contrast to piroxicam (P = 0.0001). The overall tolerability of both treatments was good. Significant differences in favour of meloxicam were observed for global efficacy assessed by the patient in RA (P < 0.05) and for overall pain intensity in OA patients (P = 0.02). In conclusion, i.m. meloxicam is safe and effective for the treatment of acute rheumatic pain and shows some superiority over piroxicam.

KEY WORDS: Meloxicam, Piroxicam, Tolerability, Intramuscular, Osteoarthritis, Rheumatoid arthritis, Non-steroidal anti-inflammatory drugs, Creatinine phosphokinase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.